Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) PT at $9.33

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have been given a consensus rating of “Hold” by the ten analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $9.33.

FULC has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “neutral” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th. Stifel Nicolaus downgraded Fulcrum Therapeutics from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $22.00 to $3.00 in a research report on Thursday, September 12th. Cantor Fitzgerald cut Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Thursday, September 12th. Bank of America lowered Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and decreased their target price for the stock from $10.00 to $2.00 in a research note on Thursday, September 12th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th.

Hedge Funds Weigh In On Fulcrum Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. National Bank of Canada FI raised its holdings in shares of Fulcrum Therapeutics by 869.6% during the 2nd quarter. National Bank of Canada FI now owns 4,460 shares of the company’s stock valued at $28,000 after buying an additional 4,000 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in Fulcrum Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock valued at $43,000 after acquiring an additional 4,701 shares during the last quarter. Walleye Capital LLC bought a new position in Fulcrum Therapeutics during the third quarter valued at approximately $59,000. Intech Investment Management LLC purchased a new position in shares of Fulcrum Therapeutics during the third quarter worth approximately $62,000. Finally, Profund Advisors LLC bought a new stake in shares of Fulcrum Therapeutics in the 2nd quarter worth approximately $68,000. 89.83% of the stock is currently owned by hedge funds and other institutional investors.

Fulcrum Therapeutics Stock Down 4.7 %

Shares of FULC opened at $4.03 on Friday. Fulcrum Therapeutics has a twelve month low of $2.86 and a twelve month high of $13.70. The stock has a market cap of $217.37 million, a PE ratio of -13.00 and a beta of 2.14. The business’s 50-day moving average price is $3.57 and its 200-day moving average price is $5.84.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.